Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04316676 · ClinicalTrials.gov registry record · NA
The MATCH Investigation: CT Myocardial Perfusion and CT-FFR vs PET MPI
A NA study, sponsored by Emory University.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT04316676 is a NA study that has completed, run by Emory University. The registered enrollment target is 20 participants.
The verdict
NCT04316676, a NA study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
The overall goal of this project is to compare the absolute quantification of myocardial perfusion done by using CT myocardial perfusion imaging (CT-MPI) and the coronary flow measured by using CT Fractional Flow Reserve analysis (CT-FFR) to the gold standard represented by PET myocardial perfusion imaging (PET-MPI).
Interventions
- DRUG Regadenoson
- DIAGNOSTIC_TEST PET-MPI Protocol
- DIAGNOSTIC_TEST CT-MPI
- DIAGNOSTIC_TEST Coronary CT angiography (CCTA) for CT-FFR calculation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-06-16 |
| Est. Completion | 2024-09-24 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04316676
The ClinicalTrials.gov registry entry for NCT04316676 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Regadenoson is the first listed.
NCT04316676 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04316676 about?
NCT04316676 is a clinical study titled "The MATCH Investigation: CT Myocardial Perfusion and CT-FFR vs PET MPI". The overall goal of this project is to compare the absolute quantification of myocardial perfusion done by using CT myocardial perfusion imaging (CT-MPI) and the coronary flow measured by using CT Fractional Flow Reserve analysis (CT-FFR) to the gold standard represented by PET myocardial perfusion ...
What is the current status of trial NCT04316676?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2021-06-16. Estimated completion is 2024-09-24.
What interventions are being tested in trial NCT04316676?
The interventions under investigation include: Regadenoson (DRUG), PET-MPI Protocol (DIAGNOSTIC_TEST), CT-MPI (DIAGNOSTIC_TEST), Coronary CT angiography (CCTA) for CT-FFR calculation (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04316676?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.